Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hikma Pharmaceuticals's Enterprise Value is £5,264 Mil.
Hikma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £280 Mil. Therefore, Hikma Pharmaceuticals's EV-to-EBIT ratio for today is 18.79.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Hikma Pharmaceuticals's Enterprise Value is £5,264 Mil.
Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £437 Mil. Therefore, Hikma Pharmaceuticals's EV-to-EBITDA ratio for today is 12.05.
Hikma Pharmaceuticals Enterprise Value Historical Data
The historical data trend for Hikma Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hikma Pharmaceuticals's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Enterprise Value falls into.
Hikma Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Hikma Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (LSE:HIK) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Hikma Pharmaceuticals's current Enterprise Value is £5,264 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £280 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Hikma Pharmaceuticals's EV-to-EBITDA for today is:
Hikma Pharmaceuticals's current Enterprise Value is £5,264 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £437 Mil.
Hikma Pharmaceuticals's current Enterprise Value is £5,264 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £2,274 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Hikma Pharmaceuticals (LSE:HIK) Business Description
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:HIK has been successfully added to your 